Stephen Sabba Buys Shares of Ligand Pharmaceuticals

On June 16, 2026, Stephen Sabba purchased 2,145 shares of Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND). The shares were bought at an average price of $66.13 each, amounting to a total value of approximately $141,848.85. This transaction was not part of a pre-arranged trading plan.

Insider Buying and Selling at Ligand Pharmaceuticals Incorporated

Stephen Sabba wasn't the only insider active recently. On the same day, he also sold 2,145 shares at a price of $254.00 each. Earlier, on June 12, Jason Haas acquired 4,000 shares at $51.56, followed by selling 6,461 shares at $255.58.

Other Institutional Activity in Ligand Pharmaceuticals

Several large funds have adjusted their positions in Ligand Pharmaceuticals. BlackRock, Inc. increased its holdings by 21,692 shares, ending with 2,961,923 shares valued at about $591.35 million. Janus Henderson Group PLC added 14,491 shares, bringing its total to 1,009,891 shares worth around $201.62 million. Invesco Ltd. made a significant addition, increasing its stake by 307,140 shares to 823,604 shares, valued at approximately $164.43 million.

Ligand Pharmaceuticals Incorporated Stock Down 3.4%

Shares of Ligand Pharmaceuticals are trading at approximately $264.41. The company has a market capitalization of $5.27 billion and a P/E ratio of 34.31. Its forward P/E is 23.25, indicating potential future earnings growth. The stock's 52-week range has been between $110.00 and $267.27, with a 50-day moving average of $229.40 and a 200-day moving average of $200.85.

Recent Earnings

Ligand Pharmaceuticals reported revenue of $274.48 million, with a revenue growth of 14.1%. The company achieved a net margin of 55.95% and a return on equity of 17.13%. Its next earnings report is scheduled for August 6, 2026.

Analysts Set New Price Targets

Analysts remain positive on Ligand Pharmaceuticals, with RBC Capital maintaining a 'buy' rating and a price target of $262 as of May 8, 2026. HC Wainwright & Co. also kept a 'buy' rating with a target of $289 on April 30, 2026. The consensus among analysts suggests a mean price target of $277.60.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company based in Jupiter, Florida. It develops and licenses a variety of biopharmaceutical assets globally, focusing on treatments for infectious diseases, multiple myeloma, and various other health conditions. The company is led by CEO Todd C. Davis and employs 47 people.

Bottom Line

Stephen Sabba's recent purchase of Ligand Pharmaceuticals shares highlights ongoing insider activity at the company. Investors often track such insider transactions for insights, but it's important to remember that these filings reflect past actions. Ligand Pharmaceuticals continues to show strong financials and positive analyst sentiment, making it a stock to watch in the biotechnology sector.